UPB presents Phase 2 VALIANT trial results at ERS Congress 2026
Upstream Bio presented results from its Phase 2 VALIANT trial of verekitug for severe asthma in an oral presentation at ERS Congress 2026.
Story updates
07:38:49 AM UTC
SquawkNews
Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma —— Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with every 12-week dosing —— The Company remains on track to initia…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.